menu
    • menu

    Company profile for T3D Therapeutics

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D=959 and has initiated pre-clinical studies in Huntington’s...
    T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D=959 and has initiated pre-clinical studies in Huntington’s Disease models. T3D-959 is designed as an orally-delivered, once-a-day medicine being evaluated for the treatment of Alzheimer’s disease patients with mild to moderate disease severity.l

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    T3D TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    68 TW Alexander Dr, Research Triangle, NC 27709
    Telephone
    Telephone
    919-237-4897
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.t3dtherapeutics.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/t3d-therapeutics-inc.
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    T3D Therapeutics Announces Results from the Phase 2 of T3D-959
    T3D Therapeutics Announces Results from the Phase 2 of T3D-959

    03 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/t3d-therapeutics-announces-positive-top-line-results-from-the-phase-2-pioneer-trial-of-t3d-959-in-mild-to-moderate-alzheimers-disease-301976115.html

    PR NEWSWIRE
    03 Nov 2023
    Share Share
    T3D Selected to Present Topline Results from Phase 2 PIONEER Study of T3D-959
    T3D Selected to Present Topline Results from Phase 2 PIONEER Study of T3D-959

    03 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/t3d-therapeutics-selected-to-present-topline-results-from-the-phase-2-pioneer-study-of-t3d-959-as-late-breaking-news-at-the-16th-clinical-trials-on-alzheimers-disease-conference-ctad-301943502.html

    PR NEWSWIRE
    03 Oct 2023
    Share Share
    T3D's Begins Enrollment in the PIONEER Phase 2 Clinical Trial of T3D-959
    T3D's Begins Enrollment in the PIONEER Phase 2 Clinical Trial of T3D-959

    11 Feb 2020

    // BUSINESSWIRE

    https://www.prnewswire.com/news-releases/t3d-therapeutics-begins-enrollment-in-the-pioneer-phase-2-clinical-trial-of-t3d-959-in-patients-with-mild-to-moderate-alzheimers-disease-301001447.html

    BUSINESSWIRE
    11 Feb 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search